Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer
Authors:
- Alissandra L. HillisAHAlissandra L. Hillis
- Timothy D. MartinTMTimothy D. Martin
- Haley E. ManchesterHMHaley E. Manchester
- Jenny HögströmJHJenny Högström
- Na ZhangNZNa Zhang
- Emmalyn LeckyELEmmalyn Lecky
- Nina KozlovaNKNina Kozlova
- Jonah LeeJLJonah Lee
- Nicole S. PerskyNPNicole S. Persky
- David E. RootDRDavid E. Root
- Myles BrownMBMyles Brown
- Karen CichowskiKCKaren Cichowski
Open Access
- 18 July 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (19) , 3250-3266
Abstract
Triple-negative breast cancer (TNBC) is responsible for a disproportionate number of breast cancer patient deaths due to extensive molecular heterogeneity, high recurrence rates, and lack of targeted therapies. Dysregulation of the phosphoinositide 3-kinase (PI3K)/AKT pathway occurs in approximately 50% of TNBC patients. Here, we performed a genome-wide CRISPR/Cas9 screen with PI3Kα and AKT inhibitors to find targetable synthetic lethalities in TNBC. Cholesterol homeostasis was identified as a collateral vulnerability with AKT inhibition. Disruption of cholesterol homeostasis with pitavastatin synergized with AKT inhibition to induce TNBC cytotoxicity in vitro in mouse TNBC xenografts and in patient-derived estrogen receptor (ER)–negative breast cancer organoids. Neither ER-positive breast cancer cell lines nor ER-positive organoids were sensitive to combined AKT inhibitor and pitavastatin. Mechanistically, TNBC cells showed impaired sterol regulatory element-binding protein 2 (SREBP-2) activation in response to single-agent or combination treatment with AKT inhibitor and pitavastatin, which was rescued by inhibition of the cholesterol-trafficking protein Niemann-Pick C1 (NPC1). NPC1 loss caused lysosomal cholesterol accumulation, decreased endoplasmic reticulum cholesterol levels, and promoted SREBP-2 activation. Taken together, these data identify a TNBC-specific vulnerability to the combination of AKT inhibitors and pitavastatin mediated by dysregulated cholesterol trafficking. These findings support combining AKT inhibitors with pitavastatin as a therapeutic modality in TNBC. Significance: Two FDA-approved compounds, AKT inhibitors and pitavastatin, synergize to induce cell death in triple-negative breast cancer, motivating evaluation of the efficacy of this combination in clinical trials.Keywords
All Related Versions
Funding Information
- National Institutes of Health (CA253097)
- Ludwig Center at Harvard (no number)
- National Science Foundation Graduate Research Fellowship Program (2020292129)
- National Institutes of Health (P01CA250959)
- Susan G. Komen (CCR18547665)
- Harvard Stem Cell Institute (DP-0194-21-00)
- Orionin Tutkimussäätiö (no number)
- Maud Kuistilan Muistosäätiö (no number)
- American Association for Cancer Research (no number)
- CHALLENGE
- National Institutes of Health (R01CA234600)
- Howard Hughes Medical Institute (no number)
- U.S. Department of War (W81XWH-20-1-0867)
This publication has 48 references indexed in Scilit:
- Statins and cancer: A systematic review and meta-analysisEuropean Journal of Cancer, 2008
- Statin-Induced Breast Cancer Cell Death: Role of Inducible Nitric Oxide and Arginase-Dependent PathwaysCancer Research, 2007
- Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNKCancer Letters, 2007
- Breast Cancer Growth Prevention by StatinsCancer Research, 2006
- Sulforhodamine B colorimetric assay for cytotoxicity screeningNature Protocols, 2006
- Protein Sensors for Membrane SterolsCell, 2006
- Chemical, pharmacokinetic and pharmacodynamic properties of statins: an updateFundamental & Clinical Pharmacology, 2004
- The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription FactorCell, 1997
- Feedback Regulation of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase in Livers of Mice Treated with Mevinolin, a Competitive Inhibitor of the ReductaseJournal of Clinical Investigation, 1980
- Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activityFEBS Letters, 1976